{"id":5656,"date":"2019-10-01T11:23:00","date_gmt":"2019-10-01T09:23:00","guid":{"rendered":"https:\/\/pikralida.eu\/project-no-rpwp-01-02-00-30-0047-19-00\/"},"modified":"2021-08-03T11:25:36","modified_gmt":"2021-08-03T09:25:36","slug":"project-no-rpwp-01-02-00-30-0047-19-00","status":"publish","type":"post","link":"https:\/\/pikralida.eu\/en\/project-no-rpwp-01-02-00-30-0047-19-00\/","title":{"rendered":"Project no. RPWP.01.02.00-30-0047\/19-00"},"content":{"rendered":"<style>.wp-block-kadence-advancedheading.kt-adv-heading_d00d29-61, .wp-block-kadence-advancedheading.kt-adv-heading_d00d29-61[data-kb-block=\"kb-adv-heading_d00d29-61\"]{font-size:20px;font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading_d00d29-61 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading_d00d29-61[data-kb-block=\"kb-adv-heading_d00d29-61\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}<\/style>\n<h2 class=\"kt-adv-heading_d00d29-61 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading_d00d29-61\">Pikralida sp. z o.o. is implementing a project, co-financed from the European Funds, entitled \u201cEstablishment of a R&amp;D Laboratory of Super Generic Drugs\u201d.<\/h2>\n\n\n\n<p>Project no. RPWP.01.02.00-30-0047\/19-00 is implemented under the Regional Operational Programme for Wielkopolskie Voivodeship 2014-2020; Priority Axis I: Innovative and Competitive Economy, Measure 1.2 Strengthening innovation potential of enterprises in of the Wielkopolskie Voivodeship.<\/p>\n\n\n\n<p>The aim of the Project is to obtain a prototype formulation of a pharmaceutical form of a tablet containing an active ingredient in an amorphous form. Moreover, under the implementation of the Project, the Beneficiary is to develop a new service to extend its offer, namely the development of an amorphisation technology of active ingredients based on hot extrusion as well as the development of drug formulations containing an amorphous form of an active ingredient, while enhancing the service of the development of analytical methods.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Project budget: PLN 1 972 710,00<\/li><li>EU funding for the Project: PLN 1,260,200.00<\/li><li>\tDuration of the Project: 01\/10\/2019 \u2013 30\/06\/2021<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/pikralida.eu\/wp-content\/uploads\/2019\/10\/EFRR_Samorzad_kolor-PL-scaled-e1625076045441.jpg\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"126\" src=\"https:\/\/pikralida.eu\/wp-content\/uploads\/2019\/10\/EFRR_Samorzad_kolor-PL-scaled-e1625076045441.jpg\" alt=\"\" class=\"wp-image-5658\"\/><\/a><\/figure>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-_d520f8-83 .kt-block-spacer{height:60px;}.wp-block-kadence-spacer.kt-block-spacer-_d520f8-83 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-_d520f8-83\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\" style=\"height:60px\"><hr class=\"kt-divider\" style=\"border-top-color:#eee;border-top-width:1px;width:80%;border-top-style:solid\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading_ebfce4-c5, .wp-block-kadence-advancedheading.kt-adv-heading_ebfce4-c5[data-kb-block=\"kb-adv-heading_ebfce4-c5\"]{font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading_ebfce4-c5 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading_ebfce4-c5[data-kb-block=\"kb-adv-heading_ebfce4-c5\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}<\/style>\n<h5 class=\"kt-adv-heading_ebfce4-c5 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading_ebfce4-c5\">Co-funded projects:<\/h5>\n\n\n<style>.kb-posts-id-_95d32f-13 .entry.loop-entry .entry-header .entry-title{font-size:16px;line-height:18px;letter-spacing:0.9px;}<\/style><ul class=\"wp-block-kadence-posts kb-posts kadence-posts-list kb-posts-id-_95d32f-13 content-wrap grid-cols kb-posts-style-boxed grid-sm-col-2 grid-lg-col-3 item-image-style-above\"><li class=\"kb-post-list-item\">\n\t<article class=\"entry content-bg loop-entry kb-post-no-image post-5606 post type-post status-publish format-standard has-post-thumbnail hentry category-grants\">\n\t\t\t\t<div class=\"entry-content-wrap\">\n\t\t\t<header class=\"entry-header\">\n\t<h2 class=\"entry-title\"><a href=\"https:\/\/pikralida.eu\/en\/project-no-poir-01-01-01-00-0072-21\/\" rel=\"bookmark\">Project no. POIR.01.01.01-00-0072\/21<\/a><\/h2><\/header><!-- .entry-header -->\n\t<div class=\"entry-summary\">\n\t\t<p>Development of an innovative pilot line and its validation under real conditions using synthesis process of a model active pharmaceutical ingredient.<\/p>\n\t<\/div><!-- .entry-summary -->\n\t<footer class=\"entry-footer\">\n\t<\/footer><!-- .entry-footer -->\t\t<\/div>\n\t<\/article>\n<\/li>\n<li class=\"kb-post-list-item\">\n\t<article class=\"entry content-bg loop-entry kb-post-no-image post-5310 post type-post status-publish format-standard has-post-thumbnail hentry category-grants\">\n\t\t\t\t<div class=\"entry-content-wrap\">\n\t\t\t<header class=\"entry-header\">\n\t<h2 class=\"entry-title\"><a href=\"https:\/\/pikralida.eu\/en\/project-no-poir-01-01-01-00-0235-20\/\" rel=\"bookmark\">Project no. POIR.01.01.01-00-0235\/20<\/a><\/h2><\/header><!-- .entry-header -->\n\t<div class=\"entry-summary\">\n\t\t<p>Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.<\/p>\n\t<\/div><!-- .entry-summary -->\n\t<footer class=\"entry-footer\">\n\t<\/footer><!-- .entry-footer -->\t\t<\/div>\n\t<\/article>\n<\/li>\n<li class=\"kb-post-list-item\">\n\t<article class=\"entry content-bg loop-entry kb-post-no-image post-5338 post type-post status-publish format-standard has-post-thumbnail hentry category-grants\">\n\t\t\t\t<div class=\"entry-content-wrap\">\n\t\t\t<header class=\"entry-header\">\n\t<h2 class=\"entry-title\"><a href=\"https:\/\/pikralida.eu\/en\/project-no-poir-04-01-04-00-0063-20-00\/\" rel=\"bookmark\">Project no. POIR.04.01.04-00-0063\/20-00<\/a><\/h2><\/header><!-- .entry-header -->\n\t<div class=\"entry-summary\">\n\t\t<p>Development of the innovative formulation of the combination drug dedicated for the geriatric patients in pain pharmacotherapy<\/p>\n\t<\/div><!-- .entry-summary -->\n\t<footer class=\"entry-footer\">\n\t<\/footer><!-- .entry-footer -->\t\t<\/div>\n\t<\/article>\n<\/li>\n<li class=\"kb-post-list-item\">\n\t<article class=\"entry content-bg loop-entry kb-post-no-image post-5314 post type-post status-publish format-standard has-post-thumbnail hentry category-grants\">\n\t\t\t\t<div class=\"entry-content-wrap\">\n\t\t\t<header class=\"entry-header\">\n\t<h2 class=\"entry-title\"><a href=\"https:\/\/pikralida.eu\/en\/project-no-tango-iv-c-0012-2019\/\" rel=\"bookmark\">Project no. TANGO-IV-C\/0012\/2019<\/a><\/h2><\/header><!-- .entry-header -->\n\t<div class=\"entry-summary\">\n\t\t<p>Development of an innovative combined preparation dedicated for the treatment of hypertension.<\/p>\n\t<\/div><!-- .entry-summary -->\n\t<footer class=\"entry-footer\">\n\t<\/footer><!-- .entry-footer -->\t\t<\/div>\n\t<\/article>\n<\/li>\n<li class=\"kb-post-list-item\">\n\t<article class=\"entry content-bg loop-entry kb-post-no-image post-5656 post type-post status-publish format-standard hentry category-grants\">\n\t\t\t\t<div class=\"entry-content-wrap\">\n\t\t\t<header class=\"entry-header\">\n\t<h2 class=\"entry-title\"><a href=\"https:\/\/pikralida.eu\/en\/project-no-rpwp-01-02-00-30-0047-19-00\/\" rel=\"bookmark\">Project no. RPWP.01.02.00-30-0047\/19-00<\/a><\/h2><\/header><!-- .entry-header -->\n\t<div class=\"entry-summary\">\n\t\t<p>Establishment of a R&#038;D Laboratory of Super Generic Drugs.<\/p>\n\t<\/div><!-- .entry-summary -->\n\t<footer class=\"entry-footer\">\n\t<\/footer><!-- .entry-footer -->\t\t<\/div>\n\t<\/article>\n<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Establishment of a R&#038;D Laboratory of Super Generic Drugs.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[],"class_list":["post-5656","post","type-post","status-publish","format-standard","hentry","category-grants"],"_links":{"self":[{"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/posts\/5656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/comments?post=5656"}],"version-history":[{"count":0,"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/posts\/5656\/revisions"}],"wp:attachment":[{"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/media?parent=5656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/categories?post=5656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pikralida.eu\/en\/wp-json\/wp\/v2\/tags?post=5656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}